[go: up one dir, main page]

MX2019008038A - Composiciones y metodos para tratar la enfermedad de farber. - Google Patents

Composiciones y metodos para tratar la enfermedad de farber.

Info

Publication number
MX2019008038A
MX2019008038A MX2019008038A MX2019008038A MX2019008038A MX 2019008038 A MX2019008038 A MX 2019008038A MX 2019008038 A MX2019008038 A MX 2019008038A MX 2019008038 A MX2019008038 A MX 2019008038A MX 2019008038 A MX2019008038 A MX 2019008038A
Authority
MX
Mexico
Prior art keywords
compositions
methods
farber disease
treating farber
treating
Prior art date
Application number
MX2019008038A
Other languages
English (en)
Inventor
H Schuchman Edward
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of MX2019008038A publication Critical patent/MX2019008038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proveen proteínas, composiciones y métodos para tratar la enfermedad de Farber.
MX2019008038A 2017-01-13 2018-01-12 Composiciones y metodos para tratar la enfermedad de farber. MX2019008038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446166P 2017-01-13 2017-01-13
PCT/US2018/013509 WO2018132667A1 (en) 2017-01-13 2018-01-12 Compositions and methods for treating farber disease

Publications (1)

Publication Number Publication Date
MX2019008038A true MX2019008038A (es) 2020-02-05

Family

ID=62839661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008038A MX2019008038A (es) 2017-01-13 2018-01-12 Composiciones y metodos para tratar la enfermedad de farber.

Country Status (8)

Country Link
US (4) US20190343936A1 (es)
EP (2) EP3568154B1 (es)
JP (3) JP7576293B2 (es)
AU (2) AU2018207564A1 (es)
CA (1) CA3049771A1 (es)
JO (1) JOP20190164B1 (es)
MX (1) MX2019008038A (es)
WO (1) WO2018132667A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008038A (es) * 2017-01-13 2020-02-05 Icahn School Med Mount Sinai Composiciones y metodos para tratar la enfermedad de farber.
EP3648776A4 (en) * 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN-VITRO AND IN-VIVO ENRICHMENT STRATEGY AGAINST LYMPHOCYTE FROM VECTOR-TRANSDUCED HSC FOR THE TREATMENT OF DISEASES
KR20250016468A (ko) 2018-02-02 2025-02-03 엔지반트 테라퓨틱스 게엠베하 파버병을 치료하는 방법
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051020T2 (hu) * 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
WO2014160390A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
MX2019008038A (es) * 2017-01-13 2020-02-05 Icahn School Med Mount Sinai Composiciones y metodos para tratar la enfermedad de farber.
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
KR20250016468A (ko) * 2018-02-02 2025-02-03 엔지반트 테라퓨틱스 게엠베하 파버병을 치료하는 방법

Also Published As

Publication number Publication date
CA3049771A1 (en) 2018-07-19
US20190343936A1 (en) 2019-11-14
JP2024169509A (ja) 2024-12-05
EP3568154A4 (en) 2020-11-18
US20240075113A1 (en) 2024-03-07
JP2023011938A (ja) 2023-01-24
WO2018132667A1 (en) 2018-07-19
JOP20190164B1 (ar) 2023-09-17
JP2020514305A (ja) 2020-05-21
JP7576293B2 (ja) 2024-10-31
EP3568154B1 (en) 2023-07-12
JOP20190164A1 (ar) 2019-07-02
EP4295903A2 (en) 2023-12-27
EP3568154A1 (en) 2019-11-20
US20220313800A1 (en) 2022-10-06
AU2018207564A1 (en) 2019-08-08
US20250170225A1 (en) 2025-05-29
EP4295903A3 (en) 2024-03-27
AU2025200254A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MY203971A (en) Anti-lag-3 antibodies and compositions
GB2541571A (en) Pharmaceutical compositions
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MY191581A (en) Anti-pd-1 antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2021006326A (es) Inhibidores de pcna.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12017500602A1 (en) Methods for treating ocular conditions
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EA201591709A1 (ru) 5-бром-индирубины
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas